{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:24:11Z","timestamp":1793391851498,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014421","name":"EA Pharma Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cgh.2024.08.004","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T21:17:50Z","timestamp":1724793470000},"page":"748-757.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study"],"prefix":"10.1016","volume":"23","author":[{"given":"Naomi","family":"Uemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Haruma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Kushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2024.08.004_bib1","article-title":"Adverse effects associated with proton pump inhibitor use","volume":"13","author":"Yibirin","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.cgh.2024.08.004_bib2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bcpt.13023","article-title":"Side effects of long-term proton pump inhibitor use: a review","volume":"123","author":"Haastrup","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.cgh.2024.08.004_bib3","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/ctg.2015.18","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese\/non-Japanese subjects","volume":"6","author":"Sakurai","year":"2015","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2024.08.004_bib4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s10620-017-4866-6","article-title":"Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases","volume":"63","author":"Yang","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2024.08.004_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.111.185314","article-title":"Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438)","volume":"339","author":"Shin","year":"2011","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2024.08.004_bib6","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.14309\/ajg.0000000000001735","article-title":"Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects","volume":"117","author":"Laine","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.08.004_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12876-023-02772-w","article-title":"Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis","volume":"23","author":"Haruma","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cgh.2024.08.004_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000484217","article-title":"Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective cross-sectional study","volume":"97","author":"Kojima","year":"2018","journal-title":"Digestion"},{"key":"10.1016\/j.cgh.2024.08.004_bib9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/apt.13324","article-title":"Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology","volume":"42","author":"Lundell","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.08.004_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819834511","article-title":"Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence","volume":"12","author":"Cheung","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2024.08.004_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010623.pub2","article-title":"Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions","author":"Song","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2024.08.004_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017739","article-title":"Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden","volume":"7","author":"Brusselaers","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.cgh.2024.08.004_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00535-022-01861-z","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021","volume":"57","author":"Iwakiri","year":"2022","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2024.08.004_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.08.004_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan versus lansoprazole for healing and maintenance of healing of rrosive rsophagitis: a randomized trial","volume":"164","author":"Laine","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.08.004_bib16","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3748\/wjg.v24.i14.1550","article-title":"Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole","volume":"24","author":"Ashida","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.08.004_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.08.004_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CEG.S144149","article-title":"Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis","volume":"11","author":"Uemura","year":"2018","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.cgh.2024.08.004_bib19","first-page":"397","article-title":"Multiple gastric carcinoids and endocrine cell micronests in type A gastritis: nuclear morphometric and immunohistochemical analysis","volume":"13","author":"Iwai","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.cgh.2024.08.004_bib20","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/gutjnl-2017-314852","article-title":"Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study","volume":"67","author":"Kawai","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.08.004_bib21","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/gutjnl-2017-314010","article-title":"Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study","volume":"67","author":"Mizokami","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.08.004_bib22","doi-asserted-by":"crossref","first-page":"G997","DOI":"10.1152\/ajpgi.2001.281.4.G997","article-title":"PACAP stimulates gastric acid secretion in the rat by inducing histamine release","volume":"281","author":"Sandvik","year":"2001","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2024.08.004_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/gut.39.5.649","article-title":"Marked increase in gastric acid secretory capacity after omeprazole treatment","volume":"39","author":"Waldum","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.08.004_bib24","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.2169\/internalmedicine.2857-23","article-title":"Multiple gastric neuroendocrine tumors associated with long-term use of a proton pump inhibitor and a potassium-competitive acid blocker","volume":"63","author":"Nagao","year":"2024","journal-title":"Intern Med"},{"key":"10.1016\/j.cgh.2024.08.004_bib25","first-page":"209","article-title":"A\u00a0gastric neuroendocrine tumor after prolonged use of proton pump inhibitors","volume":"115","author":"Prado","year":"2023","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.cgh.2024.08.004_bib26","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.2169\/internalmedicine.1265-22","article-title":"Prevalence of raspberry-type gastric foveolar-type tumor in individuals undergoing medical checkups","volume":"62","author":"Sakamoto","year":"2023","journal-title":"Intern Med"},{"key":"10.1016\/j.cgh.2024.08.004_bib27","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.ajpath.2022.06.005","article-title":"KLF4 mutation shapes pathologic characteristics of foveolar-type gastric adenoma in helicobacter pylori-naive patients","volume":"192","author":"Mishiro","year":"2022","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cgh.2024.08.004_bib28","doi-asserted-by":"crossref","first-page":"E784","DOI":"10.1055\/a-0854-3818","article-title":"Gastric foveolar-type adenomas endoscopically showing a raspberry-like appearance in the Helicobacter pylori -uninfected stomach","volume":"7","author":"Shibagaki","year":"2019","journal-title":"Endosc Int Open"},{"key":"10.1016\/j.cgh.2024.08.004_bib29","first-page":"54","article-title":"Gastric polyps: a retrospective cohort analysis of 23,668 endoscopies indicates changing epidemiological and phenotypic characteristics","volume":"19","author":"Kapizioni","year":"2024","journal-title":"Prz Gastroenterol"},{"key":"10.1016\/j.cgh.2024.08.004_bib30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/MEG.0000000000002587","article-title":"The association between duration of and indications for proton pump inhibitor use and risk of gastric polyps","volume":"35","author":"Kroupa","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.08.004_bib31","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524007705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524007705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:29:35Z","timestamp":1778617775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356524007705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1542356524007705"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2024.08.004","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2024.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}